遗传风险评分在卒中研究与临床中的应用
本文综述遗传风险评分(GRS)在卒中研究及临床中的应用。缺血性卒中遗传度高达39%、脑出血29%,GRS可整合多基因变异用于个体化风险分层,在房颤患者缺血性卒中风险分层、抗凝使用者脑出血风险评估及卒中幸存者血管危险因素控制预测中展现潜在价值,但其跨人群适用性受限于全基因组关联研究多基于欧洲血统人群。
要点
- 缺血性卒中遗传度高达39%,脑出血遗传度达29%。
- GRS在人群层面预防首次卒中事件有较强预测潜力,临床整合仍有限。
- GRS跨人群适用性受限,因全基因组关联研究多基于欧洲血统人群。
核心结论
- GRS整合多基因变异可补充传统临床模型进行个体化风险分层,但临床整合仍有限。
- GRS跨人群适用性有限,因多数全基因组关联研究基于欧洲血统人群。
研究设计与样本
- 综述,基于下一代测序与全基因组关联研究进展,汇总卒中遗传风险评分相关证据。
主要发现
- 缺血性卒中遗传度估计高达39%,脑出血遗传度达29%。
- GRS在人群层面对首次卒中事件显示较强预测潜力,临床整合仍有限。
- 新兴证据提示GRS可在房颤患者缺血性卒中风险分层、抗凝使用者脑出血风险评估及卒中幸存者血管危险因素控制预测中增加价值。
关键数值与推荐
- 缺血性卒中遗传度估计高达39%,脑出血遗传度达29%。
临床怎么用
- GRS有望用于房颤患者缺血性卒中风险分层。
- GRS有望用于抗凝使用者脑出血风险评估。
- GRS有望用于预测卒中幸存者血管危险因素控制。
- GRS与多组学数据及机器学习结合可能进一步优化风险评估,推动一、二级预防的个体化策略。
局限性
- GRS跨人群适用性有限,因多数全基因组关联研究基于欧洲血统人群。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Stroke remains a leading cause of death and disability worldwide. While well-established risk factors play a major role, genetic predisposition is a crucial determinant of stroke susceptibility, with heritability estimates up to 39% for ischemic stroke and 29% for intracerebral hemorrhage. Advances in next-generation sequencing and genome-wide association studies have identified numerous genetic loci associated with stroke risk, paving the way for the development of genetic risk scores. These scores aggregate information from multiple genetic variants to estimate an individual's stroke risk, offering a promising tool for personalized risk stratification that complements traditional clinical models. While GRSs have demonstrated strong predictive potential for primary stroke events in population-based settings, their integration into clinical practice remains limited. Emerging evidence suggests that GRSs could add value in clinical decision-making, for instance, for stratifying ischemic stroke risk in patients with atrial fibrillation, assessing intracerebral hemorrhage risk in anticoagulant users, and predicting vascular risk factor control in stroke survivors. The incorporation of GRSs with multiomics data and machine learning may further refine risk assessment, driving personalized prevention strategies for both primary and secondary stroke prevention. A major challenge is the limited applicability of GRS across diverse populations, as most genome-wide association studies have been conducted in individuals of European ancestry. Addressing this limitation is critical for ensuring equitable and effective implementation of GRSs in clinical settings. As methodologies continue to evolve, integrating GRS into stroke research could significantly enhance risk assessment and support precision medicine approaches tailored to individual patients.
引用
- Bragazzi NL, Zhang L, Omarov M, et al. Genetic Risk Scores in Stroke Research and Care. Stroke. 2025. PMID: 40396275. doi:10.1161/STROKEAHA.125.050961
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。